Saturday 17 October 2026
Export EBS’s income statement to Excel — free account
Emergent Biosolutions Inc.
EBS Healthcare Drug Manufacturers Specialty & Generic
Emergent Biosolutions Inc.’s revenue for fiscal 2025 (year ended December 2025) was $742.9 million, down 28.8% from fiscal 2024. In the quarter to June 2026, revenue grew 66.3%, EPS fell 1,486.4%, free cash flow fell 47.7% and total debt fell 12.9%, each against the same quarter a year earlier.
6.38
0.80
−11.14%
Follow EBS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
13.92% | 10.46% | (1.60%) | (40.29%) | |
Piotroski F-Score |
5 | 6 | 5 | 5 | |
| 5.17% | 3.88% | (0.63%) | (13.95%) | ||
ROIC |
7.43% | 7.06% | 4.06% | (5.27%) | |
Return on Tangible Assets |
8.82% | 7.15% | (1.25%) | (24.51%) | |
Average Days of Receivables |
69.17 | 41.37 | 65.58 | 90.04 | |
Free Cash Flow per Share |
0.75 | 3.64 | 2.61 | 1.67 | |
Free Cash Flow |
39.90 | 195.00 | 135.50 | 86.10 | |
Capital Expenditures |
26.90 | 24.40 | (12.50) | (11.60) | |
| Other line items | |||||
Cash ROIC |
2.67% | 14.96% | 10.77% | 8.09% | |
Accounts Receivable Turnover |
5.83 | 6.22 | 4.16 | 5.71 | |
Accounts Payable Turnover |
5.15 | 5.60 | 6.35 | 5.97 | |
Inventory Turnover |
1.06 | 1.00 | 0.97 | 1.06 | |
Average Days of Payables |
58.31 | 62.21 | 46.55 | 53.91 | |
Days of Inventory on Hand |
361.95 | 384.25 | 386.10 | 326.02 | |
Tax Rate |
(0.28) | (0.36) | (3.46) | 0.21 | |
Research and Development Expense of Revenue |
6.36% | 7.16% | 7.18% | 5.88% | |
Selling, General and Administrative Expense of Revenue |
24.82% | 25.05% | 26.64% | 23.53% | |
Share Based Compensation of Revenue |
1.93% | 2.18% | 2.45% | 2.45% | |
Interest Coverage |
2.00 | 1.69 | 1.09 | (1.30) | |
Operating CF/Net income |
0.17 | 3.24 | (17.21) | (0.55) | |
Depreciation/Fixed assets |
0.51 | 0.51 | 0.52 | 0.58 | |
Capex/Depreciation |
0.25 | 0.23 | (0.12) | (0.11) | |
Revenue per Share |
14.83 | 13.89 | 13.04 | 14.93 | |
Operating CF per Share |
0.24 | 3.19 | 2.85 | 1.89 | |
Capex per Share |
0.51 | 0.46 | (0.24) | (0.22) | |
Capex to Sales |
(0.03) | (0.03) | 0.02 | 0.02 |
Columns are period end dates